This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in…
- Investigator
- Eric Papierniak
- Status
- Accepting Candidates
- Ages
- 12 Years - N/A
- Sexes
- All